Ghulam Rehman Mohyuddin
( out of 139 reviews )

Ghulam Rehman Mohyuddin, MBBS

Languages spoken: English, Hindi, Pushto, Urdu

Clinical Locations

Huntsman Cancer Institute - Cancer Research North

Clinic 2D/E, BMT/Hematology
Salt Lake City

  • Dr. Mohyuddin completed his medical training at the prestigious Aga Khan University in Pakistan. He completed his internal medicine residency at the University of Kansas where he developed a passion for medical education and treating hematological malignancies. After residency, he pursued Chief Residency at the University of Kansas, focusing on mechanisms of novel educational delivery and improving access to research for trainees. He completed his fellowship at the University of Kansas, developing a clinical and research interest in multiple myeloma, drug repurposing, quality of scientific methods, end of life, cost-effective/evidence-based care and medical education. He enjoys the outdoors tremendously, and that drew him to life in Utah where he is currently an Assistant Professor at the Huntsman Cancer Institute with a focus on multiple myeloma. His clinical interests focus on the treatment of multiple myeloma (MM), including bone marrow transplantation, with specific research interests including the design and quality of clinical trials in MM and other hematological malignancies, renal failure, supportive and palliative care in MM and bone marrow transplant recipients, medical education, drug repurposing, cost-effective are and risk adapted/personalized therapies for patients with plasma cell dycrasias. His work has been published in various high impact medical journals including Lancet Hematology, Blood Advances, British Journal of Hematology and American Journal of Hematology.

    Specialties

    Board Certification

    American Board of Internal Medicine (Dual Sub: Hematology and Medical Oncology)
    American Board of Internal Medicine (Internal Medicine)

    Patient Rating

    4.9 /5
    ( out of 139 reviews )

    The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers.

    The scale on which responses are measured is 1 to 5 with 5 being the best score.

    Patient Comments

    Patient comments are gathered from our patient experience survey and displayed in their entirety.
    Patients are de-identified for confidentiality and patient privacy.

    September 19, 2024
    HUNTSMAN CANCER CENTER

    Dr Mohy is a very caring, concerned Dr. towards his patients.would highly recommend him and Huntsman to anyone needing treatment.

    September 12, 2024
    HUNTSMAN CANCER CENTER

    Dr. Mohy Ud Din is a physician with a caring approach that develops an intervention plan that is understandable to the patient.

    September 07, 2024
    HUNTSMAN CANCER CENTER

    Both were very good at looking for the real issues with my heath. I know I'm in good hands not just a number. Thank you!

    September 05, 2024
    HUNTSMAN CANCER CENTER

    One of the best doctors I have ever had. Has a good manner about him listen carefully , makes good informed decisions based on my needs.

    July 26, 2024
    HUNTSMAN CANCER CENTER

    I feel well cared for and listened to

    July 24, 2024
    HUNTSMAN CANCER CENTER

    Very very knowledgeable, and competent explained everything on my level. OUTSTANDING.

    July 03, 2024
    HUNTSMAN CANCER CENTER

    The doctor is always very kind and very professional. He conveys a sense of understanding of my needs and the best medical practices to apply to those knees. I enjoy my visits with the doctor.

    June 21, 2024
    HUNTSMAN CANCER CENTER

    Appreciate working with him, he is kind, and a good listner

    June 20, 2024
    HUNTSMAN CANCER CENTER

    I love Dr. Manny. He seems genuinely concerned for me and my health and is trying to help me as best he can.

    See More Patient Comments

  • Dr. Mohyuddin completed his medical training at the prestigious Aga Khan University in Pakistan. He completed his internal medicine residency at the University of Kansas where he developed a passion for medical education and treating hematological malignancies. After residency, he pursued Chief Residency at the University of Kansas, focusing on mechanisms of novel educational delivery and improving access to research for trainees. He completed his fellowship at the University of Kansas, developing a clinical and research interest in multiple myeloma, drug repurposing, quality of scientific methods, end of life, cost-effective/evidence-based care and medical education. He enjoys the outdoors tremendously, and that drew him to life in Utah where he is currently an Assistant Professor at the Huntsman Cancer Institute with a focus on multiple myeloma. His clinical interests focus on the treatment of multiple myeloma (MM), including bone marrow transplantation, with specific research interests including the design and quality of clinical trials in MM and other hematological malignancies, renal failure, supportive and palliative care in MM and bone marrow transplant recipients, medical education, drug repurposing, cost-effective are and risk adapted/personalized therapies for patients with plasma cell dycrasias. His work has been published in various high impact medical journals including Lancet Hematology, Blood Advances, British Journal of Hematology and American Journal of Hematology.

    Board Certification and Academic Information

    Academic Departments Internal Medicine -Primary
    Academic Divisions Hematology & Hematologic Malignancies
    Board Certification
    American Board of Internal Medicine (Dual Sub: Hematology and Medical Oncology)
    American Board of Internal Medicine (Internal Medicine)

    Education history

    Fellowship Hematology-Oncology - University of Kansas Medical Center Fellow
    Internal Medicine - University of Kansas Medical Center Chief Resident
    Residency Internal Medicine Categorical Residency - University of Kansas Medical Center Resident
    Medicine, Surgery - Aga Khan University, Medical College M.B.B.S.

    Selected Publications

    Journal Article

    1. Wagner CB, Julian K, Bryan B, Steinbach MN, Shewan S, Maxwell L, Vigil M, Mohyuddin GR, Godara A, McClune B, Galarza Fortuna G, Sborov D (2024). Novel chemotherapy combination of carfilzomib with dexamethasone, cyclophosphamide, etoposide and cisplatin (K-DCEP) for the treatment of relapsed/refractory aggressive plasma cell dyscrasias. Leuk Lymphoma, 1-4. (Read full article)
    2. Mohyuddin GR, Goodman AM (2024). Overtreatment of multiple myeloma and its precursor states: de-escalation is an urgent need in clinical practice and trials. Nat Rev Clin Oncol. (Read full article)
    3. Mellgard G, Gilligan M, Cliff ERS, Bhutani D, Mohyuddin GR, Eisenberger A, Lentzsch S, Chakraborty R (2024). Risk stratification models overestimate progression risk in contemporary patients with smoldering multiple myeloma. Hemasphere, 8(3), e61. (Read full article)
    4. Ilerhunmwuwa NP, Abdul Khader AHS, Smith C, Cliff ERS, Booth CM, Rd EH, Aziz M, Lee-Smith W, Goodman A, Chakraborty R, Mohyuddin GR (2024). Dietary interventions in cancer: a systematic review of all randomized controlled trials. J Natl Cancer Inst. (Read full article)
    5. Mian H, Seow H, Pond GR, Gayowsky A, Foley R, Balistky A, Ebraheem M, Cipkar C, Sapru H, Mohyuddin GR, Hadidi SA, Visram A (2024). Treatment Pattern, Healthcare Resource Utilization and Symptom Burden Among Patients with Triple Class Exposed Multiple Myeloma: A Population-Based Cohort Study. Clin Lymphoma Myeloma Leuk. (Read full article)
    6. Neupane K, Fortuna GG, Dahal R, Schmidt T, Fonseca R, Chakraborty R, Koehn KA, Mohan M, Mian H, Costa LJ, Sborov D, Mohyuddin GR (2024). Alterations in chromosome 1q in multiple myeloma randomized clinical trials: a systematic review. Blood Cancer J, 14(1), 20. (Read full article)
    7. Balaban N, Mohyuddin GR, Kashi A, Massarweh A, Markel G, Bomze D, Goldstein DA, Meirson T (2023). Projecting complete redaction of clinical trial protocols (RAPTURE): redacted cross sectional study. BMJ, 383, e077329. (Read full article)
    8. Abusamak AA, Abusamak M, Al-Abbadi M, Rayyan A, Oran O, Mohyuddin GR, Kelkar AH, Goodman AM, Chakraborty R, Cliff ERS, Al Hadidi S (2023). Use of subjective minimizing language at hematology and oncology conferences: A systematic review. J Cancer Policy, 39, 100461. (Read full article)
    9. Najjar M, McCarron J, Cliff ERS, Berger K, Steensma DP, Al Hadidi S, Chakraborty R, Goodman A, Anto E, Greene T, Sborov D, Mohyuddin GR (2023). Adverse Event Reporting in Randomized Clinical Trials for Multiple Myeloma. JAMA Netw Open, 6(11), e2342195. (Read full article)
    10. Alrawabdeh J, Alzubi M, Alzyoud M, Odeh N, Hamadneh Y, Mian H, Mohyuddin GR, Kelkar AH, Goodman AM, Chakraborty R, Russler-Germain DA, Mehra N, Baggio D, Cliff ERS, Al Hadidi S (2023). Characteristics of post hoc subgroup analyses of oncology clinical trials: a systematic review. JNCI Cancer Spectr, 7(6). (Read full article)
    11. Mohyuddin GR, Chakraborty R, Cliff ERS, Derman BA (2023). Clinician preferences on treatment of smoldering myeloma: a cross-sectional survey. EClinicalMedicine, 65, 102272. (Read full article)
    12. Mohyuddin GR, Prasad V (2023). Detecting Selection Bias in Observational Studies-When Interventions Work Too Fast. JAMA Intern Med, 183(9), 897-898. (Read full article)
    13. Hentzen S, Meirson T, Koehn K, Goodman A, Chakraborty R, Sborov D, Rubinstein S, Mohyuddin GR (2023). Attrition and withdrawal in multiple myeloma randomized controlled trials: A systematic review. Eur J Haematol, 111(3), 491-498. (Read full article)
    14. Booth CM, Sengar M, Goodman A, Wilson B, Aggarwal A, Berry S, Collingridge D, Denburg A, Eisenhauer EA, Ginsburg O, Goldstein D, Gunasekera S, Hammad N, Honda K, Jackson C, Karikios D, Knopf K, Koven R, Marini BL, Maskens D, Moraes FY, Mohyuddin GR, Poudyal BS, Pramesh CS, Roitberg F, Rubagumya F, Schott S, Sirohi B, Soto-Perez-de-Celis E, Sullivan R, Tannock IF, Trapani D, Tregear M, van der Graaf W, Vanderpuye V, Gyawali B (2023). Common Sense Oncology: outcomes that matter. Lancet Oncol, 24(8), 833-835. (Read full article)
    15. Mian A, Naqvi SAA, Ayaz A, Husnain M, Aljama MA, Mohyuddin GR, Koehn K, Mohan M, Bin Riaz I, Chakraborty R (2023). Incidence of second primary malignancies in patients with multiple myeloma receiving anti-CD38 monoclonal antibodies: A systematic review and meta-analysis. Leuk Res, 131. (Read full article)
    16. Mian A, Naqvi SAA, Ayaz A, Husnain M, Aljama MA, Mohyuddin GR, Koehn K, Mohan M, Bin Riaz I, Chakraborty R (2023). Incidence of second primary malignancies in patients with multiple myeloma receiving anti-CD38 monoclonal antibodies: A systematic review and meta-analysis. Leuk Res, 131, 107324. (Read full article)
    17. Reynolds G, Cliff ERS, Mohyuddin GR, Popat R, Midha S, Ng Liet Hing M, Harrison SJ, Kesselheim A, Teh BW (2023). Infections following bispecific antibodies in myeloma: a systematic review and meta-analysis. Blood Adv. (Read full article)
    18. McCurdy A, Seow H, Pond GP, Gayowsky A, Chakraborty R, Visram A, Kaedbey R, DSouza A, Mohyuddin GR, Wildes TM, Fonseca R, Mian H (2023). Cancer-specific mortality in multiple myeloma: a population-based retrospective cohort study. Haematologica. (Read full article)
    19. Sengar M, Hopman WM, Mohyuddin GR, Goodman AM, Gyawali B, Mukherji D, Hammad N, Pramesh CS, Aggarwal A, Sullivan R, Booth CM (2023). Randomised controlled trials evaluating anticancer therapies in haematological cancers: an overview of global research activity. Ecancermedicalscience, 17, 1558. (Read full article)
    20. Abdallah AO, Mahmoudjafari Z, Ahmed N, Cui W, Shune L, McGuirk J, Mohan M, Mohyuddin GR, Afrough A, Alkharabsheh O, Atrash S (2023). Clinical efficacy of retreatment of daratumumab-based therapy (D2) in daratumumab-refractory multiple myeloma. Eur J Haematol, 110(6), 626-632. (Read full article)
    21. Sharma N, Wayant C, Neupane K, Lenka J, Berger K, Goodman AM, Booth CM, Prasad V, Mohyuddin GR (2023). Quality of content reporting on two major oncology media websites: OncLive and Targeted Oncology. J Cancer Policy, 36, 100411. (Read full article)
    22. Bindal P, Najjar M, Koehn K, Godara A, Sborov DW, McClune B, Julian K, Wagner C, Mohyuddin GR (2023). Refractoriness to last line of therapy: how often is it mandated and reported? A systematic review of randomized myeloma trials. Leuk Lymphoma, 1-4. (Read full article)
    23. Tariq SM, Abdallah AO, Goodman A, Sborov D, Mohyuddin GR, Britt A (2023). The Landscape of Currently Enrolling Maintenance Trials in Multiple Myeloma. Clin Hematol Int. (Read full article)
    24. Sawalha L, Kelkar AH, Mohyuddin GR, Goodman AM, Gagelmann N, Al Hadidi S (2023). Analysis of repeated roles in editorial boards at oncology focused journals. J Cancer Policy, 35. (Read full article)
    25. Mohyuddin GR, Chakraborty R, SchefferCliff ER (2023). The promise and harms of screening for plasma cell dyscrasias. Br J Haematol. (Read full article)
    26. Mohyuddin GR, Meirson T (2023). A critical appraisal of the ATLAS trial of maintenance therapy for multiple myeloma: end points, censoring and equipoise. Nat Rev Clin Oncol. (Read full article)
    27. Sengar M, Hopman WM, Mohyuddin GR, Goodman AM, Gyawali B, Mukherji D, Hammad N, Pramesh CS, Aggarwal A, Sullivan R, Booth CM (2023). Randomised controlled trials evaluating anticancer therapies in haematological cancers: an overview of global research activity. Ecancermedicalscience, 17. (Read full article)
    28. Vardell VA, Ermann DA, Tantravahi SK, Haaland B, McClune B, Godara A, Mohyuddin GR, Sborov DW (2022). Impact of academic medical center access on outcomes in multiple myeloma. Am J Hematol, 98(1), 41-48. (Read full article)
    29. Etekal T, Koehn K, Sborov DW, McClune B, Prasad V, Haslam A, Berger K, Booth C, Al Hadidi S, Abdallah AO, Goodman A, Mohyuddin GR (2022). Time-to-event surrogate end-points in multiple myeloma randomised trials from 2005 to 2019: A surrogacy analysis. Br J Haematol. (Read full article)
    30. Mohyuddin GR, Sinnarajah A, Gayowsky A, Chan KKW, Seow H, Mian H (2022). Quality of end-of-life care in multiple myeloma: A 13-year analysis of a population-based cohort in Ontario, Canada. Br J Haematol, 199(5), 688-695. (Read full article)
    31. Atieh T, Atrash S, Ahmed N, Mohan M, Cui W, Shune L, Hajjar S, Mahmoudjafari Z, Quick J, Wishna A, Riffel J, McGuirk J, Mohyuddin GR, Abdallah AO (2022). Belantamab in Combination with Dexamethasone in Patients with Triple-class Relapsed/Refractory Multiple Myeloma. Clin Lymphoma Myeloma Leuk, 22(12), 912-919. (Read full article)
    32. Mohyuddin GR, Ahlstrom JM, Chmielewski CA, Sweeney NW, Molina TH, Cheung CS, Ballard EW, Seng FF, Van Oekelen O, Godara A, McClune B, Sborov D (2022). A survey on the patient perspective on cure in multiple myeloma. Lancet Haematol, 9(10), e716-e719. (Read full article)
    33. Cliff ERS, Mohyuddin GR (2022). Overall survival as a primary end point in multiple myeloma trials. Nat Rev Clin Oncol, 19(9), 565-566. (Read full article)
    34. Mohyuddin GR, Mehra N, Ryll B, Prasad V (2022). Control participants of randomised trials: an often forgotten, vulnerable population. Lancet Haematol, 9(9), e634-e636. (Read full article)
    35. McInturf G, Younger K, Sanchez C, Walde C, Abdallah AO, Ahmed N, Shune L, Sborov DW, Godara A, McClune B, Sinclair CT, Mohyuddin GR (2022). Palliative care utilization, transfusion burden, and end-of-life care for patients with multiple myeloma. Eur J Haematol, 109(5), 559-565. (Read full article)
    36. Fatoki RA, Koehn K, Kelkar A, Al Hadidi S, Mehra N, Mian H, Landgren O, Kazandjian D, Hoffman J, Sborov DW, Mohyuddin GR (2022). Global Myeloma Trial Participation and Drug Access in the Era of Novel Therapies. JCO Glob Oncol, 8, e2200119. (Read full article)
    37. Gil K, Abbasi S, Mehta K, McClune B, Sborov D, Ahmed N, Abdallah AO, Ganguly S, McGuirk J, Shune L, Mohyuddin GR (2022). Trends in Inpatient Chemotherapy Hospitalizations, Cost and Mortality for Patients with Acute Leukemias and Myeloma. Clin Hematol Int, 4(1-2), 56-59. (Read full article)
    38. Wesson W, Galate VL, Sborov DW, McClune B, Goodman AM, Gyawali B, Prasad V, Abbasi S, Mohyuddin GR (2022). Characteristics of clinical trials for haematological malignancies from 2015 to 2020: A systematic review. Eur J Cancer, 167, 152-160. (Read full article)
    39. Ouchveridze E, Banerjee R, Desai A, Aziz M, Lee-Smith W, Mian H, Berger K, McClune B, Sborov D, Qazilbash M, Kumar S, Mohyuddin GR (2022). Financial toxicity in hematological malignancies: a systematic review. Blood Cancer J, 12(4), 74. (Read full article)
    40. Berger K, Mohyuddin GR (2022). Reporting of trials with possible detrimental overall survival: a patient advocate perspective. Lancet Haematol, 9(2), e94. (Read full article)
    41. Mohyuddin GR, Mian H (2021). Daratumumab in newly diagnosed MM - incorporating lessons learnt from CASSIOPEIA, MAIA and beyond. Nat Rev Clin Oncol, 19(1), 3-4. (Read full article)
    42. Mohyuddin GR, Atieh T, Ahmed N, Sborov D, McClune B, Abdallah AO, Goodman AM, Aziz M, Allen I, Prasad V (2021). Intention to treat versus modified intention-to-treat analysis in B-cell maturation antigen and CD19 chimeric antigen receptor trials: A systematic review and meta-analysis. Eur J Cancer, 156, 164-174. (Read full article)
    43. Abdallah AO, Mohyuddin GR, Ahmed N, Mohan M, Cui W, Shune L, Mahmoudjafari Z, McGuirk J, Ganguly S, Atrash S (2021). Outcomes of VDPACE with an immunomodulatory agent as a salvage therapy in relapsed/refractory multiple myeloma with extramedullary disease. EJHaem, 2(4), 757-764. (Read full article)
    44. Mohyuddin GR, Banerjee R, Alam Z, Berger KE, Chakraborty R (2021). Rethinking mechanisms of neurotoxicity with BCMA directed therapy .Crit Rev Oncol Hematol. 2021 Aug 27:103453. doi: 10.1016/j.critrevonc.2021.103453. Online ahead of print.PMID: 34461271 Review. Online prior to print. (2021.103453).
    45. Mohyuddin GR, Atieh T, Ahmed N, Sborov D, McClune B, Abdallah AO, Goodman AM, Aziz M, Allen I, Prasad V (2021). Intention to treat versus modified intention-to-treat analysis in B-cell maturation antigen and CD19 chimeric antigen receptor trials: A systematic review and meta-analysis. 156(October 2021), 164-174.
    46. Pennipede D, Mohyuddin GR, Hawkins R, Ganguly S, Shune L, Ahmed N, Mohan M, Cui W, Mahmoudjafari Z, McGuirk J, Atrash S, Abdallah AO (2021). Carfilzomib, Cyclophosphamide, and Dexamethasone (KCd) for the Treatment of Triple-class Relapsed/Refractory Multiple Myeloma (RRMM). Eur J Haematol. (Read full article)
    47. Mohyuddin GR, Hampton J, Aziz M, Khuder S, Malik S, McClune B, Abdallah AO (2021). A Systematic Review and Network Meta-analysis of Randomized Data on Efficacy of Novel Therapy Combinations in Patients with Lenalidomide-refractory Multiple Myeloma. Clin Lymphoma Myeloma Leuk, 21(7), 489-496. (Read full article)
    48. Balmaceda N, Aziz M, Chandrasekar VT, McClune B, Kambhampati S, Shune L, Abdallah AO, Anwer F, Majeed A, Qazilbash M, Ganguly S, McGuirk J, Mohyuddin GR (2021). Infection risks in multiple myeloma: a systematic review and meta-analysis of randomized trials from 2015 to 2019. BMC Cancer, 21(1), 730. (Read full article)
    49. Ferguson JE, Vetos D, Ho BV, Aziz M, Lee WM, Mohyuddin GR, Prouty M (2021). Trends in diversity of participants in dermatology clinical trials over time: A systematic review. J Am Acad Dermatol. (Read full article)
    50. Mohyuddin GR, Koehn K, Shune L, Aziz M, Abdallah AO, McClune B, Ganguly S, McGuirk J, Kambhampati S (2021). Renal insufficiency in multiple myeloma: a systematic review and meta-analysis of all randomized trials from 2005-2019. Leuk Lymphoma, 62(6), 1386-1395. (Read full article)
    51. Mohyuddin GR, Koehn K, Abdallah AO, W Sborov D, Rajkumar SV, Kumar S, McClune B (2021). Use of endpoints in multiple myeloma randomized controlled trials over the last 15 years: A systematic review. Am J Hematol, 96(6), 690-697. (Read full article)
    52. Mohyuddin GR, Abdallah AO, McClune B (2021). Caution With Routine Use of Daratumumab for Newly Diagnosed High-Risk Multiple Myeloma. JAMA Oncol, 7(4), 635. (Read full article)
    53. Mohyuddin GR, Koehn K, Sborov D, McClune B, Abdallah AO, Goodman AM, Prasad V (2020). Quality of control groups in randomised trials of multiple myeloma enrolling in the USA: a systematic review. Lancet Haematol, 8(4), e299-e304. (Read full article)
    54. Mohyuddin GR, Koehn K, Abdallah AO, Goodman AM, Prasad V (2021). Reporting of Postprotocol Therapies and Attrition in Multiple Myeloma Randomized Clinical Trials: A Systematic Review. JAMA Netw Open, 4(4), e218084. (Read full article)
    55. Abbasi S, Roller J, Abdallah AO, Shune L, McClune B, Sborov D, Mohyuddin GR (2021). Hospitalization at the end of life in patients with multiple myeloma. BMC Cancer, 21(1), 339. (Read full article)
    56. Mohyuddin GR, Rooney A, Balmaceda N, Aziz M, Sborov DW, McClune B, Kumar SK (2020). Chimeric antigen receptor T-cell therapy in multiple myeloma: a systematic review and meta-analysis of 950 patients. Blood Adv, 5(4), 1097-1101. (Read full article)
    57. Mohyuddin GR, Lester K, Thomas L, Eck LM, Newman JR (2021). Implementation of an Audience Response System in a Case Conference Curriculum: Results of a Placebo-Controlled Trial. Cureus, 13(2), e13512. (Read full article)
    58. Abdallah AO, Mohyuddin GR, Mahmoudjafari Z, Atrash S, Kawsar H, Sigle M, Shune L, McGuirk J, Ganguly S (2020). Outcomes of Daratumumab, Pomalidomide, and Dexamethasone, Followed by High-dose Chemotherapy and Autologous Stem Cell Transplantation, in Patients With Relapsed/Refractory Multiple Myeloma. Clin Lymphoma Myeloma Leuk, 21(2), e212-e219. (Read full article)
    59. Abdallah AO, Sigle M, Mohyuddin GR, Coggins E, Remker C, Shune L, Mahmoudjafari Z, McGuirk J, Ganguly S (2020). Outcomes of VD-PACE With Immunomodulatory Agent as a Salvage Therapy for Relapsed/Refractory Multiple Myeloma. Clin Lymphoma Myeloma Leuk, 21(2), e220-e226. (Read full article)
    60. Gaudel P, Mohyuddin GR, Fields-Meehan J (2021). Nivolumab Use for First-Line Management of Hepatocellular Carcinoma: Results of a Real-World Cohort of Patients. Fed Pract, 38(2), 89-91. (Read full article)
    61. Mohyuddin GR, Abbasi S, Okoniewski M, McClune B, Abdallah AO, Ganguly S, McGuirk J, Shune L (2020). Inpatient mortality of patients with multiple myeloma and renal impairment undergoing autologous stem cell transplantation. Eur J Haematol, 105(5), 571-577. (Read full article)
    62. Mohyuddin GR, Koehn K, Costa L, Kumar SK, McClune B (2020). Enrolment of racial minorities across 15 years of multiple myeloma randomised trials; calling on researchers to become agents of change. Lancet Haematol, 7(10), e704-e706. (Read full article)
    63. Dominick A, Mohyuddin GR, Fields-Meehan J, Mathur S (2020). Combination Immunotherapy Associated With Severe Hepatotoxicity and Fatal Aplastic Anemia. Am J Ther. (Read full article)
    64. Britt A, Mohyuddin GR, McClune B, Singh A, Lin T, Ganguly S, Abhyankar S, Shune L, McGuirk J, Skikne B, Godwin A, Pessetto Z, Golem S, Divine C, Dias A (2020). Acute myeloid leukemia or myelodysplastic syndrome with chromosome 17 abnormalities and long-term outcomes with or without hematopoietic stem cell transplantation. Leuk Res, 95, 106402. (Read full article)
    65. Mohyuddin GR, Aziz M, Britt A, Wade L, Sun W, Baranda J, Al-Rajabi R, Saeed A, Kasi A (2020). Similar response rates and survival with PARP inhibitors for patients with solid tumors harboring somatic versus Germline BRCA mutations: a Meta-analysis and systematic review. BMC Cancer, 20(1), 507. (Read full article)
    66. Britt A, Mohyuddin GR, Al-Rajabi R (2020). Maintenance of Stable Disease in Metastatic Perivascular Epithelioid Cell Tumor of the Liver With Single-Agent Sorafenib. Am J Ther. (Read full article)
    67. Mohyuddin GR, Dominick A, Black T, Hoffman M, Male H, Byrd K, McClune B, Eck L, Neupane P (2020). A Critical Appraisal and Targeted Intervention of the Oncology Experience in an Internal Medicine Residency. J Cancer Educ. (Read full article)
    68. Mohyuddin GR, Aziz M, McClune B, Abdallah AO, Qazilbash M (2020). Antibiotic prophylaxis for patients with newly diagnosed multiple myeloma: Systematic review and meta-analysis. Eur J Haematol, 104(5), 420-426. (Read full article)
    69. Mohyuddin GR, Jobe A, Thomas L (2020). Does Use of High-fidelity Simulation Improve Resident Physician Competency and Comfort Identifying and Managing Bradyarrhythmias? Cureus, 12(2), e6872. (Read full article)
    70. Al-Kofahi M, Mohyuddin GR, Taylor ME, Eck LM (2019). Reducing Resident Physician Workload to Improve Well Being. Cureus, 11(6), e5039. (Read full article)
    71. Mohyuddin GR, Romanelli N, Shune L, Abhyankar S, Ganguly S, McGuirk J, Singh A (2018). Autologous hematopoietic stem cell transplant is safe for elderly lymphoma patients. Hematol Oncol Stem Cell Ther, 12(2), 124-125. (Read full article)
    72. Mohyuddin GR, Isom N, Thomas L (2019). Applying the Principles of Bloom's Taxonomy to Managing Tachyarrhythmia: Results of a Tachyarrhythmia Workshop. Cureus, 11(2), e4037. (Read full article)
    73. Mohyuddin GR, Qazilbash M (2018). The role of NK Cells in Multiple Myeloma.
    74. Mohyuddin GR, Clark AE, Roller J, Shune L, Lin T, Dunavin N, Dias A, Ganguly S, Abhyankar S, McGuirk J, Singh A (2017). Utility of routine surveillance imaging for diffuse large B-cell lymphoma post autologous transplant: A single center experience. Hematol Oncol Stem Cell Ther, 11(3), 135-141. (Read full article)
    75. Mohyuddin GR, Clark AE, Roller J, Shune L, Lin T, Dunavin N, Dias A, Ganguly S, Abhyankar S, McGuirk J, Singh A (2018). Utility of Routine Surveillance Imaging for Hodgkin Disease following Autologous Transplant: Experiences from a Single Institution. Acta Haematol, 139(1), 52-57. (Read full article)
    76. Mohyuddin GR, Uy J, Medhavi H, Faisal MS, Qazilbash MH (2017). Immune-Mediated Neuropathies following Autologous Stem Cell Transplantation for Multiple Myeloma: Case Series and Review of the Literature. Acta Haematol, 137(2), 86-88. (Read full article)
    77. Parkash O, Mohyuddin GR, Ayub A, Nazir I, Maan AA, Hamid S (2017). Electrophysiological changes in patients with liver cirrhosis in a tertiary care hospital in Karachi, Pakistan. J Ayub Med Coll Abbottabad, 28(4), 676-679. (Read full article)
    78. Mohyuddin GR, Alam Z, Malik UZ, Shakil O, ul Haq A (2016). REVISED TRAUMA SCORE AS A PREDICTOR OF OUTCOME IN TRAUMA CASES: EXPERIENCES AT A TERTIARY CARE HOSPITAL IN KARACHI, PAKISTAN. J Ayub Med Coll Abbottabad, 27(3), 584-6. (Read full article)
    79. Mohyuddin GR, Al Asad M, Scratchko L, Khaleeq G (2013). Acute generalized exanthematous pustulosis with multiple organ dysfunction syndrome. Am J Crit Care, 22(3), 270-3. (Read full article)
    80. Mohyuddin GR, Rabinowitz I (2013). A patient with chronic lymphocytic leukemia and acquired angioedema: Correlation of clinical and biochemical response to CLL therapy. Ecancermedicalscience, 7(1). (Read full article)
    81. Khan C, Mohyuddin GR (2013). Bone Marrow Biopsy Simulation Training for Fellows. 4(4).
    82. Mohyuddin GR, Qureshi R (2012). Recommendation for use of Vitamin ‘D’ Treatment during Pregnancy. 4, 223-6.

    Review

    1. Beechinor RJ, Mohyuddin GR, Mitchell DE, Aaron D, Mahmoudjafari Z (2023). The story of the development of generic lenalidomide: How one company thwarted the Hatch-Waxman Act to generate billions of dollars in revenue. [Review]. J Cancer Policy, 38, 100446. (Read full article)
    2. Steinbach M, Neupane K, Aziz M, Lee-Smith W, Julian K, Godara A, McClune B, Kelkar AH, Sborov D, Mohyuddin GR (2023). Multiple Myeloma in Young Patients: A Scoping Review. [Review]. Clin Lymphoma Myeloma Leuk, 24(1), 15-22. (Read full article)
    3. Ouchveridze E, Berger K, Mohyuddin GR (2022). Value in Myeloma Care: Myth or Reality. [Review]. Curr Hematol Malig Rep, 17, 206-216. (Read full article)
    4. Wayant C, Mohyuddin GR, Prasad V (2022). The accelerated approval pathway in oncology: Balancing the benefits and potential harms. [Review]. J Cancer Policy, 32, 100323. (Read full article)
    5. Mohyuddin GR, Banerjee R, Alam Z, Berger KE, Chakraborty R (2021). Rethinking mechanisms of neurotoxicity with BCMA directed therapy. [Review]. Crit Rev Oncol Hematol, 166, 103453. (Read full article)

    Case Report

    1. Yacoub A, Mohyuddin GR, Nazzaro JM (2019). Bilateral subthalmic nucleus deep brain stimulation with microelectrode recordings in the setting of mild inherited hemophilia B: a case report. Int J Neurosci, 129(9), 933-935. (Read full article)
    2. Jobe AL, Ahonen KT, Poplin V, Rao S, Mohyuddin GR (2018). Afatinib-induced Interstitial Lung Disease Successfully Treated with Corticosteroids: Case Report and Review of the Literature. Cureus, 10(6), e2805. (Read full article)
    3. Mohyuddin GR, Yacoub A (2016). Primary Myelofibrosis Presenting as Extramedullary Hematopoiesis in a Transplanted Liver Graft: Case Report and Review of the Literature. Case Rep Hematol, 2016, 9515404. (Read full article)
    4. Mohyuddin GR, Male HJ (2016). A Rare Cause of Hemophagocytic Lymphohistiocytosis: Fusobacterium Infection-A Case Report and Review of the Literature. Case Rep Hematol, 2016, 4839146. (Read full article)
    5. Mohyuddin GR, Sultan F, Zhang K, Khaleeq G (2013). Sulfasalazine induced lung toxicity masquerading as sarcoidosis--case report and review of the literature. Sarcoidosis Vasc Diffuse Lung Dis, 30(3), 226-30. (Read full article)
    6. Moosajee SM, Mohyuddin GR, Khan S, Kamal AK (2013). Acute acquired demyelinating polyneuropathy–an initial presentation of diffuse large B cell lymphoma. 4(1), 35-8.
    7. Mohyuddin G, Rabinowitz I (2013). A patient with chronic lymphocytic leukemia and acquired angioedema: correlation of clinical and biochemical response to CLL therapy. Ecancermedicalscience, 7, 292. (Read full article)
    8. Mohyuddin GR, Sultan F, Khaleeq G (2012). A rare presentation of a rare disease: pulmonary lymphomatoid granulomatosis. Case Rep Pulmonol, 2012, 371490. (Read full article)

    Editorial

    1. Smith C, Booth CM, Mohyuddin GR (2024). Dietary interventions, statistical power, and unanswered questions. J Natl Cancer Inst, 116(8), 1404-1405. (Read full article)
    2. Mohyuddin GR, Banerjee R, Goodman AM (2021). Lack of equipoise in the LIGHTHOUSE trial for patients with relapsed multiple myeloma: An ethical concern. Eur J Cancer, 157, 533-535. (Read full article)

    Letter

    1. Chakraborty R, Cheruvalath H, Patwari A, Szabo A, Schinke C, Dhakal B, Lentzsch S, DSouza A, Mohyuddin GR, Julian K, Midha S, Costello P, Kaiser M, Hing MNL, Harrison SJ, Cliff ERS, Mohan M (2024). Sustained remission following finite duration bispecific antibody therapy in patients with relapsed/refractory myeloma. [Letter to the editor]. Blood Cancer J, 14(1), 137. (Read full article)
    2. Mohyuddin GR, Rubinstein SM, Kumar S, Rajkumar SV, Fonseca R, Abdallah NH, Calip GS, Wang X, Parrinello CM, Sborov D (2024). Performance of newer myeloma staging systems in a contemporary, large patient cohort. [Letter to the editor]. Blood Cancer J, 14(1), 95. (Read full article)
    3. Gong Z, Umoru G, Monge J, Shah N, Mohyuddin GR, Radhakrishnan SV, Chakraborty R, Rasche L, Schinke C, DSouza A, Mohan M (2024). Adverse effects and non-relapse mortality of BCMA directed T cell therapies in multiple myeloma: an FAERS database study. [Letter to the editor]. Blood Cancer J, 14(1), 36. (Read full article)
    4. Chakraborty R, Hadidi SA, Scheffer Cliff ER, Mohyuddin GR (2023). Is aggressive treatment of smoldering myeloma the path to curing myeloma? [Letter to the editor]. Blood Adv, 7(15), 3932-3935. (Read full article)
    5. Beechinor RJ, Mahmoudjafari Z, Mohyuddin GR (2023). Financial Toxicity in Oncology, More Unanswered Questions. [Letter to the editor]. J Clin Oncol, JCO2300915. (Read full article)
    6. Tariq SM, Abdallah AO, Goodman A, Sborov D, Mohyuddin GR, Britt A (2023). The Landscape of Currently Enrolling Maintenance Trials in Multiple Myeloma [Letter to the editor]. Clin Hematol Int, 5(2-3), 170-176. (Read full article)
    7. Mohyuddin GR, Goodman AM (2023). Ineligible for transplant, but eligible for intensive quadruplet therapy-The value of 'add-on' trials for vulnerable patient populations. [Letter to the editor]. Eur J Cancer, 185, 164-166. (Read full article)
    8. Cliff ERS, Reynolds G, Popat R, Teh BW, Kesselheim AS, Mohyuddin GR (2023). Acknowledging Infection Risk in Bispecific Antibody Trials in the Treatment of Multiple Myeloma. [Letter to the editor]. J Clin Oncol, 41(10), 1949-1951. (Read full article)
    9. Mohyuddin GR, Kapur R, Costa L (2023). Inclusion criteria of currently enrolling T-cell engaging trials in multiple myeloma: Should we be focusing on lines of prior therapy? [Letter to the editor]. Br J Haematol. (Read full article)
    10. Ouchveridze E, Booth C, Mohyuddin GR (2023). Subgroups and precision in myeloma [Letter to the editor]. J Cancer Policy, 35. (Read full article)
    11. Bindal P, Najjar M, Koehn K, Godara A, Sborov DW, McClune B, Jullian K, Wagner C, Mohyuddin GR (2023). Refractoriness to last line of therapy: how often is it mandated and reported? A systematic review of randomized myeloma trials [Letter to the editor]. Leuk Lymphoma. (Read full article)
    12. Mohyuddin GR, Chakraborty R, Calip GS, Ascha MS, Wang X, Rubinstein SM, Tuchman S, Costa L, Haaland B, Giri S, Mian H, Fonseca R, Sborov D (2022). Prognostic value of translocation 11;14 in patients with relapsed/refractory myeloma receiving anti-CD38 therapy. [Letter to the editor]. Blood Cancer J, 12(12), 168. (Read full article)
    13. Van Oekelen O, Birrer N, Wesson W, Galate VL, Cliff ERS, Goodman AM, Abdallah AO, Chakraborty R, Prasad V, Mohyuddin GR (2022). Characteristics of measurable residual disease assessment in myeloma: a review of clinical trials from 2015-2020. [Letter to the editor]. Blood Cancer J, 12(11), 155. (Read full article)
    14. Cliff ERS, Mian H, Mohyuddin GR (2022). Teclistamab in Relapsed or Refractory Multiple Myeloma [Letter to the editor]. N Engl J Med, 387(18), 1721-1722. (Read full article)
    15. Goodman AM, Mohyuddin GR, Prasad V (2022). Ivosidenib and Azacitidine in IDH1-Mutated AML. [Letter to the editor]. N Engl J Med, 386(26), 2536. (Read full article)
    16. Gil K, Abbasi S, Mehta K, McClune B, Sborov D, Ahmed N, Abdallah AO, Ganguly S, McGuirk J, Shune L, Mohyuddin GR (2022). Trends in Inpatient Chemotherapy Hospitalizations, Cost and Mortality for Patients with Acute Leukemias and Myeloma [Letter to the editor]. Clin Hematol Int, 4(1-2), 56-59. (Read full article)
    17. Soomro MA, Hoffman J, Goodman AM, Sborov DW, Mohyuddin GR (2022). Heterogeneity of enrolment criteria for ongoing smouldering myeloma trials. [Letter to the editor]. Br J Haematol, 197(6), e86-e88. (Read full article)
    18. Banerjee R, Midha S, Kelkar AH, Goodman A, Prasad V, Mohyuddin GR (2021). Synthetic control arms in studies of multiple myeloma and diffuse large B-cell lymphoma. [Letter to the editor]. Br J Haematol, 196(5), 1274-1277. (Read full article)
    19. Meirson T, Markel G, Prasad V, Goodman AM, Mohyuddin GR (2022). Post-protocol therapy and informative censoring in the CANDOR study. [Letter to the editor]. Lancet Oncol, 23(3), e97. (Read full article)
    20. Mohyuddin GR, Goodman AM, Knopf K (2021). Perils of Ignoring Overall Survival in Interpreting the Myeloma Literature. [Letter to the editor]. J Clin Oncol, 40(1), 105-106. (Read full article)
    21. Mohyuddin GR, Ouchveridze E, Goodman A, Prasad V (2021). The landscape of trials for smoldering multiple myeloma: endpoints, trial design, and lessons learnt. [Letter to the editor]. Leuk Lymphoma, 1-3. (Read full article)
    22. Mohyuddin GR, Abdallah AO, McClune B, Goodman A, Prasad V (2020). Multiple myeloma triplet therapies: baseline characteristics and control groups. [Letter to the editor]. Lancet, 397(10285), 1620-1621. (Read full article)
    23. Mohyuddin GR, Okoniewski M, Diab O, Ganguly S, Shune L, Abdallah AO, McGuirk J, McClune B (2020). Maintenance regimens after a second autologous transplant for multiple myeloma. [Letter to the editor]. Leuk Lymphoma, 62(3), 758-760. (Read full article)
    24. Ripp J, Mohyuddin GR, Al-Jumayli M, Huang C (2021). Outcomes in older patients with NSCLC receiving immunotherapy: A single center experience. [Letter to the editor]. J Geriatr Oncol. (Read full article)
    25. Mohyuddin GR, Abbasi S, Ripp J, Singh A, Kambhampati S, McClune B (2020). Patients with leukemia dying in the hospital: results of the national inpatient sample and a call to do better. [Letter to the editor]. Leuk Lymphoma, 61(11), 2760-2762. (Read full article)
    26. Mohyuddin GR, Sigle M, Chandrasekar VT, Aziz M, Abdallah AO, Shune L, McClune B (2020). Impact of anti-CD38 therapy in multiple myeloma with high-risk cytogenetics: systematic review and meta-analysis. [Letter to the editor]. Leuk Lymphoma, 61(10), 2519-2522. (Read full article)
    27. Abbasi S, Britt A, McClune B, Shune L, Kambhampati S, Mohyuddin GR (2020). Inpatient hospitalization's associated cost and mortality in myeloma patients undergoing autologous stem cell transplant: a 13-year analysis of the National Inpatient Sample. [Letter to the editor]. Leuk Lymphoma, 61(5), 1254-1256. (Read full article)
    28. Mohyuddin GR, Roller J, Shune L, Lin T, Dias A, Ganguly S, Abhyankar S, McGuirk J, Singh A (2018). Epstein-Barr viremia and post-transplant lymphoproliferative disorders in patients undergoing haploidentical stem cell transplantation with post-transplant cyclophosphamide. [Letter to the editor]. Hematol Oncol Stem Cell Ther, 12(3), 171-173. (Read full article)
    29. Mohyuddin GR, Faisal MS, Badar T, Shah N, Bashir Q, Patel KK, Hosing C, Popat UR, Rondon G, Delgado R, Shah JJ, Weber DM, Thomas SK, Manasanch EE, Orlowski RZ, Champlin RE, Qazilbash MH (2017). A case control study of syngeneic transplantation versus autologous transplantation for multiple myeloma: two decades of experiences from a single center. [Letter to the editor]. Leuk Lymphoma, 59(2), 515-518. (Read full article)